Researchers at NYU Langone Health developed a new drug that targets mutant HER2 cancer proteins without harming healthy cells ...

For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between ...

A new study describes the development of a biologic, a drug derived from natural biological systems, that targets a mutant cancer protein called HER2 (human epidermal growth factor receptor 2) without ...

Scientists at NYU have created a drug that targets cancer-causing HER2 mutations without harming healthy cells. This new ...

Antibodies show promise as candidates for therapeutics as well as tools for advancing mechanistic studies of the HER family receptors.

2024 年 10 月 9 日，德曲妥珠单抗获得国家药品监督管理局（NMPA）批准上市，用于治疗存在人表皮生长因子受体 ...

Triple-negative breast cancer (TNBC): The breast tissue lacks estrogen receptors, progesterone receptors, and HER2 protein ...

Drs Kathy Miller and Nancy U. Lin discuss central nervous system involvement in HER2 positive breast cancer, including the biology and management of patients.

Because of technological advancements in healthcare, the market is expected to reach USD 1779.8 million by 2033.“Increased ...

A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly cause disease progression and metastasis, leading ...

These breakthrough therapies have not only improved survival rates but also provided more targeted, less invasive options.

EMA committee recommends extended authorization for BeiGene’s Tevimbra to treat gastric or gastroesophageal junction cancer & ESCC: San Mateo, California Wednesday, October 23, ...